Compare Boston Scientific Corporation (BSX) vs Garmin Ltd. (GRMN) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

Garmin (GRMN) trades at $310.89, up 2.96% today and near its all-time high, with a bullish technical trend supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.81 versus $2.30 expected, and raised full-year guidance. Revenue growth is robust, driven by the fitness segment, with 2025 revenue at $7.25 billion and net income margin of 24.47%.

Outlook is positive due to sustained demand for wearables and upward revisions, but risks include rich valuations (P/E of 32.08) and potential growth deceleration. Analyst consensus is cautious with 74% hold ratings, though the price target of $318.67 suggests modest upside. Investors should weigh strong fundamentals against high expectations.